PM
RNTX

Prosight Management’s Rein Therapeutics RNTX Stock Holding History

Prosight Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$535K Sell
411,600
-31,000
-7% -$38.5K 0.09% 45
2025
Q4 		$513K Sell
442,600
-125,298
-22% -$173K 0.11% 38
2025
Q3 		$650K Buy
567,898
+139,979
+33% +$178K 0.15% 38
2025
Q2 		$599K Sell
427,919
-2,081
-0.5% -$3.75K 0.15% 36
2025
Q1 		$761K Buy
430,000
+25,021
+6% +$52.5K 0.25% 35
2024
Q4 		$931K Buy
404,979
+32,822
+9% +$99.4K 0.26% 34
2024
Q3 		$1.32M Buy
372,157
+107,157
+40% +$286K 0.32% 38
2024
Q2 		$734K Buy
+265,000
New +$1.09M 0.22% 43

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Prosight Management's RNTX Position: Q1 2026 in Review

Prosight Management reduced its Rein Therapeutics (RNTX) stake by 7% in Q1 2026, selling an estimated $38.5K and leaving 411,600 shares worth $535K. The position accounts for 0.09% of the portfolio, ranked #45.

Prosight Management first reported a position in RNTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.32M in Q3 2024. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • Prosight Management held 411,600 shares of Rein Therapeutics worth $535K as of Q1 2026.
  • Prosight Management sold 31,000 Rein Therapeutics shares in Q1 2026, an estimated $38.5K.
  • Rein Therapeutics made up 0.09% of Prosight Management's portfolio in Q1 2026, its #45 holding.
  • Prosight Management first reported a position in Rein Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Prosight Management's Rein Therapeutics position peaked at $1.32M in Q3 2024.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on Prosight Management's 13F filing for Q1 2026, filed 15 May 2026.